Novo Nordisk has engaged in a multiyear collaboration with Replicate Bioscience, investing up to $550 million to leverage Replicate’s self-replicating RNA (srRNA) platform for therapeutic development against obesity, type 2 diabetes, and other cardiometabolic disorders. Replicate’s technology aims to utilize sustained protein production with enhanced durability relative to traditional mRNA modalities. This partnership exemplifies the ongoing innovation in RNA-based drug discovery and aligns with Novo Nordisk’s strategic expansion in metabolic disease therapeutics.